IZO:CC - Izotropic Reports Board Meeting Results
(TheNewswire)
VANCOUVER, BC – TheNewswire - January 4,2023 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a medical device company commercializing IzoView, adedicated breast CT (computed tomography) imaging platform, for themore accurate detection and diagnosis of breast cancers, reports theresults of the board meeting held December 29,2022.
The Board of Directors is pleased to report thestrengthening and refocussing of Izotropic’s management. The Companyis entering into both a critical and exciting phase in IzoView’sproduct lifecycle as it prepares for a clinical study for marketauthorization in the USA. With IzoView’s engineering recentlycompleted, showcasing of IzoView to the medical and investmentcommunities is a highly anticipated catalyst for the Company. Theboard of directors and management teams are aligned to deliver in 2023 .
The results of the board meeting are as follows:
1. Effective January 1, 2023, Executive Vice Presidentof Product Engineering Dr. Younes Achkire has been appointed ChiefOperating Officer and will be taking on more responsibilitiesassociated with the overall management and growth of the Company.
Over the past year as the Executive Vice President ofProduct Engineering, Dr. Achkire has demonstrated strong strategic andexecution skills in delivering the final industrial design for theproduct ahead of schedule. Dr. Achkire completed his Ph.D. at theUniversité Libre de Bruxelles (ULB) in Brussels, Belgium, and hisPost-Doctoral work at the California Institute of Technology (Caltech)and has over 20 years of engineering experience from startups toworking with large teams in established organizations. His more recentpositions and accomplishments include Founder and Chief TechnicalOfficer of Zap Surgical Systems, where he led the design andmanufacturing of a self-shielded radiosurgery device for head and neckcancer as well as Chief Operating Officer of Sotera Wireless, aFoxconn Health Technology company, where he grew existing devicerevenue by 30%, while designing the next generation of wireless healthmonitoring products. Prior to these positions, he was VP ofEngineering at Solyndra LLC, Engineering Manager at Applied Materials,and Design Engineer for Varian Medical Systems.
2. Effective December 31, 2022, Chief Financial OfficerMs. Jody Bellefleur, left the company to pursue other businessopportunities and Izotropic thanks her for her service. Director Mr.Ralph Proceviat, CPA, has been appointed as interim Chief FinancialOfficer, effective January 1, 2023.
Mr. Proceviat has served in a supporting role for theCompany's financial filings since joining the board in the fall of2019. He has served on the audit committee and has completed financialmodeling and projections for the Company's operational plan. Mr.Proceviat has over 35 years of experience in business, finance,markets, and operations spanning several industries operating inCanada, Europe, and the United States. He is a member of the CharteredProfessional Accountants of BC and holds a Bachelor of Commerce Degreein Management Information Systems from the University of BritishColumbia.
3. To further accelerate business development, productdevelopment, marketing, and communication initiatives as the companyenters the clinical study phase, effective January 1, 2023, ThastProjects Inc., under the direction of Company Founder Mr. Bob Thastand business partner Ms. Jaclyn Thast will be exclusively responsiblefor all public company activities and communications includinginvestor relations, marketing, advertising, content development,social media, and news releases, ensuring consistent communicationsand content delivery to the Company’s shareholders under anoperational plan approved by the board ofdirectors. Mr. Thast maintains the roles of Director and Chairman ofthe Board. Ms. Thast maintains the role of Corporate Secretary andwill resume previously held operational accounting responsibilitiesfor the Company.
4. CEO Dr. John McGraw will focus on delivering themission critical 2023 initiatives that include: strategic businessdevelopment, clinical partners development, product clinical andregulatory strategy and execution, and product commercialization, inpreparation for market authorization of IzoView in the USA.
ON BEHALF OF THE BOARD
Investor Relations Contact:
Mr. James Berard
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Ms. Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify suchinformation and statements by using words such as"anticipate," "believe," "envision,""estimate," "expect," "intend,""may," "plan," "predict,""project," "target," "potential,""will," "would," "could,""should," "continue," "contemplate" andother similar expressions and derivations thereof in connection withany discussion of future events, trends or prospects or futureoperating or financial performance, although not all forward-lookingstatements contain these identifying words.
These statements are not guarantees of performance andinvolve risks including those related to capital requirements, anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the Companynor its shareholders, officers, and consultants shall be liable forany action and the results of any action taken by any person based onthe information contained herein, including, without limitation thepurchase or sale of Company securities. Nothing in this documentshould be deemed to be medical or other advice of any kind. All imagesare for illustrative purposes only. IzoView is not yet approved forsale.
Copyright (c) 2023 TheNewswire - All rights reserved.